Literature DB >> 30935573

Reoxygenation during radiotherapy in intermediate-risk prostate cancer.

Stéphane Supiot1, Caroline Rousseau2, Mélanie Dore2, Catherine Chèze-Le-Rest3, Christine Kandel-Aznar4, Vincent Potiron2, Stéphane Guerif3, François Paris2, Ludovic Ferrer2, Loïc Campion2, Philippe Meingan5, Grégory Delpon2, Mathieu Hatt6, Dimitris Visvikis6.   

Abstract

Hypoxia is a major risk factor of prostate cancer radioresistance. We evaluated hypoxia non-invasively, using 18F-Misonidazole PET/CT prior to radiotherapy and after a dose of 20 Gy in intermediate-risk prostate cancer patients. Decreased hypoxic volumes were observed in all patients, suggesting that radiotherapy induces early prostate tumor reoxygenation.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dose painting radiotherapy; FAZA; IMRT; Misonidazole; Radioresistance

Year:  2019        PMID： 30935573     DOI： 10.1016/j.radonc.2018.12.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  6 in total

1.  Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer.

Authors:  Alice Zamagni; Michele Zanoni; Michela Cortesi; Chiara Arienti; Sara Pignatta; Antonella Naldini; Anna Sarnelli; Antonino Romeo; Anna Tesei
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

2.  High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience.

Authors:  Carlo Pietro Soatti; Durim Delishaj; Romerai D'Amico; Cristina Frigerio; Ilaria Costanza Fumagalli; Francesco Bonsignore; Giulia Sangalli; Fausto Declich; Stefano Arcangeli; Antonio Ardizzoia; Alessandro Colombo
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

3.  Dynamic Characteristics and Predictive Capability of Tumor Voxel Dose-Response Assessed Using 18F-FDG PET/CT Imaging Feedback.

Authors:  Shupeng Chen; An Qin; Di Yan
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

4.  169 Yb-based rotating shield brachytherapy for prostate cancer.

Authors:  Quentin Adams; Karolyn M Hopfensperger; Yusung Kim; Xiaodong Wu; Ryan T Flynn
Journal:  Med Phys       Date:  2020-11-01       Impact factor: 4.506

Review 5.  microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation.

Authors:  Maureen Labbé; Christianne Hoey; Jessica Ray; Vincent Potiron; Stéphane Supiot; Stanley K Liu; Delphine Fradin
Journal:  Mol Cancer       Date:  2020-03-23       Impact factor: 27.401

6.  Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.

Authors:  Hanna T Sjoberg; Yiannis Philippou; Anette L Magnussen; Iain D C Tullis; Esther Bridges; Andrea Chatrian; Joel Lefebvre; Ka Ho Tam; Emma A Murphy; Jens Rittscher; Dina Preise; Lilach Agemy; Tamar Yechezkel; Sean C Smart; Paul Kinchesh; Stuart Gilchrist; Danny P Allen; David A Scheiblin; Stephen J Lockett; David A Wink; Alastair D Lamb; Ian G Mills; Adrian Harris; Ruth J Muschel; Boris Vojnovic; Avigdor Scherz; Freddie C Hamdy; Richard J Bryant
Journal:  Br J Cancer       Date:  2021-06-21       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.